The industry reported 105 venture capital (VC) deals worth $4.2 billion in November 2021, compared to the last 12-month average (November 2020 to October 2021) of 173 deals worth $5.2 billion.
In June 2021, the healthcare industry reported 106 deals worth $49.7 billion as compared to the last 12-month average (June 2020 to May 2021) of 104 deals worth $23.4 billion.
Pfizer has committed $600 million to its VC fund. The Big Pharma is setting aside 25% of the money for investments in neuroscience startups, giving it a way to continue participating in the field despite its retreat from in-house R&D.